MedTrace Logo

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM

NCT06616727 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-09-27

No results posted yet for this study

Summary

A phase I study to evaluate the safety, tolerance and pharmacokinetics of SNC109 in patients with rGBM

Conditions

  • Recurrent Glioblastoma Multiforme (GBM)

Interventions

DRUG

SNC109

SNC-109 CAR-T Cells, first dose from 5×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC

Sponsors & Collaborators

  • Shanghai Simnova Biotechnology Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-26
Primary Completion
2024-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06616727 on ClinicalTrials.gov